Status: Recruiting
A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)
An 84-day, prospective, randomized (1:1) vehicle controlled, double-masked pre-market, crossover study. Subjects with moderate to severe oGVHD related Dry Eye Disease Each subject will receive both treatments in random sequence, each for 28 days, separated by a 14-day vehicle washout period.
Participants needed: 15
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Lubris Bio Pty LtdUpdated: Jan 20, 2026Locations: 3
Eligibility criteria
Have the ability to comprehend and provide a signed and dated consent form. [+9]
are currently pregnant or, [+4]